| 1 | eligible | 11,656 |
| 2 | consenting | 543 |
| 3 | ineligible | 420 |
| 4 | unfit | 154 |
| 5 | contactable | 14 |
| 6 | study-eligible | 10 |
| 7 | 2961 | 8 |
| 8 | anti-tnf-naïve | 6 |
| 9 | biologic-naive | 6 |
| 10 | cholecystectomized | 6 |
| 11 | 3764 | 5 |
| 12 | 4074 | 5 |
| 13 | pretransfused | 5 |
| 14 | 2,119 | 4 |
| 15 | dalys/year | 4 |
| 16 | ng/m³ | 4 |
| 17 | ras-wt | 4 |
| 18 | self-paying | 4 |
| 19 | spider-phobic | 4 |
| 20 | suggestible | 4 |
| 21 | telephone-screened | 4 |
| 22 | tv-positive | 4 |
| 23 | unbelted | 4 |
| 24 | vedolizumab-treated | 4 |
| 25 | 'preparing | 3 |
| 26 | 10,948 | 3 |
| 27 | 3562 | 3 |
| 28 | 3763 | 3 |
| 29 | 4308 | 3 |
| 30 | 4689 | 3 |
| 31 | 5,238 | 3 |
| 32 | 5225 | 3 |
| 33 | cells/litre | 3 |
| 34 | commitment-enhancing | 3 |
| 35 | g/mo | 3 |
| 36 | icatibant-treated | 3 |
| 37 | low-ef | 3 |
| 38 | noncase | 3 |
| 39 | noncomatose | 3 |
| 40 | opioid-addicted | 3 |
| 41 | pre-guideline | 3 |
| 42 | race-conscious | 3 |
| 43 | screening-arm | 3 |
| 44 | seasonal-dependent | 3 |
| 45 | undistracted | 3 |
| 46 | 17,641 | 2 |
| 47 | 17,923 | 2 |
| 48 | 2,384 | 2 |
| 49 | 3262 | 2 |
| 50 | 4,141 | 2 |
| 51 | 4126 | 2 |
| 52 | 5497 | 2 |
| 53 | 6,542 | 2 |
| 54 | 6766 | 2 |
| 55 | 7745 | 2 |
| 56 | 7903 | 2 |
| 57 | 9410 | 2 |
| 58 | 9722 | 2 |
| 59 | adolescent-mlh | 2 |
| 60 | behaviorally-defined | 2 |
| 61 | biased.three | 2 |
| 62 | cgycm² | 2 |
| 63 | chikv+ve | 2 |
| 64 | citable | 2 |
| 65 | clerking | 2 |
| 66 | cont-group | 2 |
| 67 | cytomegalovirus-seropositive | 2 |
| 68 | er2 | 2 |
| 69 | hcv-rna-negative | 2 |
| 70 | high-readiness | 2 |
| 71 | immunotreated | 2 |
| 72 | late-detected | 2 |
| 73 | leptin-resistance | 2 |
| 74 | level-iii | 2 |
| 75 | lge-negative | 2 |
| 76 | ng/dl.h | 2 |
| 77 | pre-tavr | 2 |
| 78 | protocol-compliant | 2 |
| 79 | prt+tme | 2 |
| 80 | tonsillectomised | 2 |
| 81 | training-group | 2 |
| 82 | ts+ | 2 |
| 83 | 'observational/descriptive | 1 |
| 84 | -23.1±7.2 | 1 |
| 85 | 0.1ng/g | 1 |
| 86 | 0.28-0.42 | 1 |
| 87 | 0.8-3.1h | 1 |
| 88 | 0.843-0.970/0.846-0.956 | 1 |
| 89 | 1.2/1 | 1 |
| 90 | 10,837 | 1 |
| 91 | 105,950 | 1 |
| 92 | 11,033 | 1 |
| 93 | 11,375 | 1 |
| 94 | 11,943 | 1 |
| 95 | 115,775 | 1 |
| 96 | 11780 | 1 |
| 97 | 13,507 | 1 |
| 98 | 14,608 | 1 |
| 99 | 14/272 | 1 |
| 100 | 15,193 | 1 |
| 101 | 15-18-year-old | 1 |
| 102 | 152,564 | 1 |
| 103 | 16,160 | 1 |
| 104 | 16,555 | 1 |
| 105 | 16,772 | 1 |
| 106 | 1752±99kcal | 1 |
| 107 | 19,172 | 1 |
| 108 | 19.3/100 | 1 |
| 109 | 2,386 | 1 |
| 110 | 2-season | 1 |
| 111 | 20,059 | 1 |
| 112 | 22,947 | 1 |
| 113 | 22/49 | 1 |
| 114 | 259euro | 1 |
| 115 | 27.1±8.9mpa | 1 |
| 116 | 33,776 | 1 |
| 117 | 34,542 | 1 |
| 118 | 37,386 | 1 |
| 119 | 377,311 | 1 |
| 120 | 38,818 | 1 |
| 121 | 399.11/qaly | 1 |
| 122 | 4,861 | 1 |
| 123 | 40,693 | 1 |
| 124 | 42,921 | 1 |
| 125 | 4346 | 1 |
| 126 | 44/107 | 1 |
| 127 | 46,271 | 1 |
| 128 | 480,903 | 1 |
| 129 | 5,590 | 1 |
| 130 | 5,993 | 1 |
| 131 | 50,451 | 1 |
| 132 | 5851 | 1 |
| 133 | 6,140 | 1 |
| 134 | 6/440 | 1 |
| 135 | 62,565 | 1 |
| 136 | 639,064 | 1 |
| 137 | 6405 | 1 |
| 138 | 6542 | 1 |
| 139 | 68,362 | 1 |
| 140 | 71,683 | 1 |
| 141 | 8,904 | 1 |
| 142 | 8.483 | 1 |
| 143 | 8456 | 1 |
| 144 | 9,169 | 1 |
| 145 | 9,340 | 1 |
| 146 | acceptable.placebo | 1 |
| 147 | antipsychotic-stabilised | 1 |
| 148 | au*min | 1 |
| 149 | caregiver/child | 1 |
| 150 | carer/patient | 1 |
| 151 | complete.159 | 1 |
| 152 | days.data | 1 |
| 153 | deep/1257 | 1 |
| 154 | deep/1365 | 1 |
| 155 | deep/2454 | 1 |
| 156 | descriptive/qualitative | 1 |
| 157 | dietary-lifestyle | 1 |
| 158 | dinoprostone-treated | 1 |
| 159 | education/work | 1 |
| 160 | elisa-negative | 1 |
| 161 | employed.the | 1 |
| 162 | flavivirus-unprimed | 1 |
| 163 | fob-positive | 1 |
| 164 | g/animal/day | 1 |
| 165 | hypertensed | 1 |
| 166 | identified-3 | 1 |
| 167 | identified.two | 1 |
| 168 | included.eleven | 1 |
| 169 | inconsistent.fourteen | 1 |
| 170 | infant/mothers | 1 |
| 171 | infants.two | 1 |
| 172 | low-vsa/cd105 | 1 |
| 173 | mirna-related | 1 |
| 174 | mpa/53°c | 1 |
| 175 | noninhibitors | 1 |
| 176 | observed.two | 1 |
| 177 | parent/girl | 1 |
| 178 | participants.three | 1 |
| 179 | participating.explanations | 1 |
| 180 | patient-fc | 1 |
| 181 | patient-parent | 1 |
| 182 | patients-four | 1 |
| 183 | patients.five | 1 |
| 184 | performed.four | 1 |
| 185 | performed.nine | 1 |
| 186 | pethema/gem | 1 |
| 187 | pg/m³ | 1 |
| 188 | picoamperes | 1 |
| 189 | pn2/3.six | 1 |
| 190 | postpterygium | 1 |
| 191 | pound50 | 1 |
| 192 | pounds/61.6 | 1 |
| 193 | pounds/63.4 | 1 |
| 194 | practise-changing | 1 |
| 195 | preadolescent-parent | 1 |
| 196 | probably/possibly | 1 |
| 197 | pubmed-indexed | 1 |
| 198 | purposively-selected | 1 |
| 199 | reported.120 | 1 |
| 200 | reported.placebo-controlled | 1 |
| 201 | retrospective/observational | 1 |
| 202 | reviparin/placebo | 1 |
| 203 | separately.most | 1 |
| 204 | sexually-experienced | 1 |
| 205 | small.most | 1 |
| 206 | smaller/short | 1 |
| 207 | smaller/shorter | 1 |
| 208 | sn-negative | 1 |
| 209 | supervisor-subordinate | 1 |
| 210 | tested.two | 1 |
| 211 | to.80 | 1 |
| 212 | track-hd | 1 |
| 213 | tru/mg | 1 |
| 214 | tumor-associated-antigens | 1 |
| 215 | use-records | 1 |
| 216 | used.five | 1 |
| 217 | youth-caregiver | 1 |
| 218 | £36.16 | 1 |
| 219 | «well-grounded | 1 |
| 220 | ±93pg/ml | 1 |
| 221 | µg/g¹ | 1 |
| 222 | β,16 | 1 |
| 1 | 'observational/descriptive | 1 |
| 2 | 'preparing | 3 |
| 3 | -23.1±7.2 | 1 |
| 4 | 0.1ng/g | 1 |
| 5 | 0.28-0.42 | 1 |
| 6 | 0.8-3.1h | 1 |
| 7 | 0.843-0.970/0.846-0.956 | 1 |
| 8 | 1.2/1 | 1 |
| 9 | 10,837 | 1 |
| 10 | 10,948 | 3 |
| 11 | 105,950 | 1 |
| 12 | 11,033 | 1 |
| 13 | 11,375 | 1 |
| 14 | 11,943 | 1 |
| 15 | 115,775 | 1 |
| 16 | 11780 | 1 |
| 17 | 13,507 | 1 |
| 18 | 14,608 | 1 |
| 19 | 14/272 | 1 |
| 20 | 15,193 | 1 |
| 21 | 15-18-year-old | 1 |
| 22 | 152,564 | 1 |
| 23 | 16,160 | 1 |
| 24 | 16,555 | 1 |
| 25 | 16,772 | 1 |
| 26 | 17,641 | 2 |
| 27 | 17,923 | 2 |
| 28 | 1752±99kcal | 1 |
| 29 | 19,172 | 1 |
| 30 | 19.3/100 | 1 |
| 31 | 2,119 | 4 |
| 32 | 2,384 | 2 |
| 33 | 2,386 | 1 |
| 34 | 2-season | 1 |
| 35 | 20,059 | 1 |
| 36 | 22,947 | 1 |
| 37 | 22/49 | 1 |
| 38 | 259euro | 1 |
| 39 | 27.1±8.9mpa | 1 |
| 40 | 2961 | 8 |
| 41 | 3262 | 2 |
| 42 | 33,776 | 1 |
| 43 | 34,542 | 1 |
| 44 | 3562 | 3 |
| 45 | 37,386 | 1 |
| 46 | 3763 | 3 |
| 47 | 3764 | 5 |
| 48 | 377,311 | 1 |
| 49 | 38,818 | 1 |
| 50 | 399.11/qaly | 1 |
| 51 | 4,141 | 2 |
| 52 | 4,861 | 1 |
| 53 | 40,693 | 1 |
| 54 | 4074 | 5 |
| 55 | 4126 | 2 |
| 56 | 42,921 | 1 |
| 57 | 4308 | 3 |
| 58 | 4346 | 1 |
| 59 | 44/107 | 1 |
| 60 | 46,271 | 1 |
| 61 | 4689 | 3 |
| 62 | 480,903 | 1 |
| 63 | 5,238 | 3 |
| 64 | 5,590 | 1 |
| 65 | 5,993 | 1 |
| 66 | 50,451 | 1 |
| 67 | 5225 | 3 |
| 68 | 5497 | 2 |
| 69 | 5851 | 1 |
| 70 | 6,140 | 1 |
| 71 | 6,542 | 2 |
| 72 | 6/440 | 1 |
| 73 | 62,565 | 1 |
| 74 | 639,064 | 1 |
| 75 | 6405 | 1 |
| 76 | 6542 | 1 |
| 77 | 6766 | 2 |
| 78 | 68,362 | 1 |
| 79 | 71,683 | 1 |
| 80 | 7745 | 2 |
| 81 | 7903 | 2 |
| 82 | 8,904 | 1 |
| 83 | 8.483 | 1 |
| 84 | 8456 | 1 |
| 85 | 9,169 | 1 |
| 86 | 9,340 | 1 |
| 87 | 9410 | 2 |
| 88 | 9722 | 2 |
| 89 | acceptable.placebo | 1 |
| 90 | adolescent-mlh | 2 |
| 91 | anti-tnf-naïve | 6 |
| 92 | antipsychotic-stabilised | 1 |
| 93 | au*min | 1 |
| 94 | behaviorally-defined | 2 |
| 95 | biased.three | 2 |
| 96 | biologic-naive | 6 |
| 97 | caregiver/child | 1 |
| 98 | carer/patient | 1 |
| 99 | cells/litre | 3 |
| 100 | cgycm² | 2 |
| 101 | chikv+ve | 2 |
| 102 | cholecystectomized | 6 |
| 103 | citable | 2 |
| 104 | clerking | 2 |
| 105 | commitment-enhancing | 3 |
| 106 | complete.159 | 1 |
| 107 | consenting | 543 |
| 108 | cont-group | 2 |
| 109 | contactable | 14 |
| 110 | cytomegalovirus-seropositive | 2 |
| 111 | dalys/year | 4 |
| 112 | days.data | 1 |
| 113 | deep/1257 | 1 |
| 114 | deep/1365 | 1 |
| 115 | deep/2454 | 1 |
| 116 | descriptive/qualitative | 1 |
| 117 | dietary-lifestyle | 1 |
| 118 | dinoprostone-treated | 1 |
| 119 | education/work | 1 |
| 120 | eligible | 11,656 |
| 121 | elisa-negative | 1 |
| 122 | employed.the | 1 |
| 123 | er2 | 2 |
| 124 | flavivirus-unprimed | 1 |
| 125 | fob-positive | 1 |
| 126 | g/animal/day | 1 |
| 127 | g/mo | 3 |
| 128 | hcv-rna-negative | 2 |
| 129 | high-readiness | 2 |
| 130 | hypertensed | 1 |
| 131 | icatibant-treated | 3 |
| 132 | identified-3 | 1 |
| 133 | identified.two | 1 |
| 134 | immunotreated | 2 |
| 135 | included.eleven | 1 |
| 136 | inconsistent.fourteen | 1 |
| 137 | ineligible | 420 |
| 138 | infant/mothers | 1 |
| 139 | infants.two | 1 |
| 140 | late-detected | 2 |
| 141 | leptin-resistance | 2 |
| 142 | level-iii | 2 |
| 143 | lge-negative | 2 |
| 144 | low-ef | 3 |
| 145 | low-vsa/cd105 | 1 |
| 146 | mirna-related | 1 |
| 147 | mpa/53°c | 1 |
| 148 | ng/dl.h | 2 |
| 149 | ng/m³ | 4 |
| 150 | noncase | 3 |
| 151 | noncomatose | 3 |
| 152 | noninhibitors | 1 |
| 153 | observed.two | 1 |
| 154 | opioid-addicted | 3 |
| 155 | parent/girl | 1 |
| 156 | participants.three | 1 |
| 157 | participating.explanations | 1 |
| 158 | patient-fc | 1 |
| 159 | patient-parent | 1 |
| 160 | patients-four | 1 |
| 161 | patients.five | 1 |
| 162 | performed.four | 1 |
| 163 | performed.nine | 1 |
| 164 | pethema/gem | 1 |
| 165 | pg/m³ | 1 |
| 166 | picoamperes | 1 |
| 167 | pn2/3.six | 1 |
| 168 | postpterygium | 1 |
| 169 | pound50 | 1 |
| 170 | pounds/61.6 | 1 |
| 171 | pounds/63.4 | 1 |
| 172 | practise-changing | 1 |
| 173 | pre-guideline | 3 |
| 174 | pre-tavr | 2 |
| 175 | preadolescent-parent | 1 |
| 176 | pretransfused | 5 |
| 177 | probably/possibly | 1 |
| 178 | protocol-compliant | 2 |
| 179 | prt+tme | 2 |
| 180 | pubmed-indexed | 1 |
| 181 | purposively-selected | 1 |
| 182 | race-conscious | 3 |
| 183 | ras-wt | 4 |
| 184 | reported.120 | 1 |
| 185 | reported.placebo-controlled | 1 |
| 186 | retrospective/observational | 1 |
| 187 | reviparin/placebo | 1 |
| 188 | screening-arm | 3 |
| 189 | seasonal-dependent | 3 |
| 190 | self-paying | 4 |
| 191 | separately.most | 1 |
| 192 | sexually-experienced | 1 |
| 193 | small.most | 1 |
| 194 | smaller/short | 1 |
| 195 | smaller/shorter | 1 |
| 196 | sn-negative | 1 |
| 197 | spider-phobic | 4 |
| 198 | study-eligible | 10 |
| 199 | suggestible | 4 |
| 200 | supervisor-subordinate | 1 |
| 201 | telephone-screened | 4 |
| 202 | tested.two | 1 |
| 203 | to.80 | 1 |
| 204 | tonsillectomised | 2 |
| 205 | track-hd | 1 |
| 206 | training-group | 2 |
| 207 | tru/mg | 1 |
| 208 | ts+ | 2 |
| 209 | tumor-associated-antigens | 1 |
| 210 | tv-positive | 4 |
| 211 | unbelted | 4 |
| 212 | undistracted | 3 |
| 213 | unfit | 154 |
| 214 | use-records | 1 |
| 215 | used.five | 1 |
| 216 | vedolizumab-treated | 4 |
| 217 | youth-caregiver | 1 |
| 218 | £36.16 | 1 |
| 219 | «well-grounded | 1 |
| 220 | ±93pg/ml | 1 |
| 221 | µg/g¹ | 1 |
| 222 | β,16 | 1 |
| 1 | ts+ | 2 |
| 2 | 19.3/100 | 1 |
| 3 | 9410 | 2 |
| 4 | reported.120 | 1 |
| 5 | 6,140 | 1 |
| 6 | 9,340 | 1 |
| 7 | 6/440 | 1 |
| 8 | 105,950 | 1 |
| 9 | pound50 | 1 |
| 10 | 16,160 | 1 |
| 11 | to.80 | 1 |
| 12 | 11780 | 1 |
| 13 | 5,590 | 1 |
| 14 | 1.2/1 | 1 |
| 15 | 377,311 | 1 |
| 16 | 42,921 | 1 |
| 17 | 4,141 | 2 |
| 18 | 17,641 | 2 |
| 19 | 50,451 | 1 |
| 20 | 5851 | 1 |
| 21 | 4,861 | 1 |
| 22 | 2961 | 8 |
| 23 | 46,271 | 1 |
| 24 | -23.1±7.2 | 1 |
| 25 | 9722 | 2 |
| 26 | 0.28-0.42 | 1 |
| 27 | 34,542 | 1 |
| 28 | 6,542 | 2 |
| 29 | 6542 | 1 |
| 30 | 3262 | 2 |
| 31 | 68,362 | 1 |
| 32 | 3562 | 3 |
| 33 | 19,172 | 1 |
| 34 | 14/272 | 1 |
| 35 | 16,772 | 1 |
| 36 | er2 | 2 |
| 37 | identified-3 | 1 |
| 38 | 480,903 | 1 |
| 39 | 7903 | 2 |
| 40 | 17,923 | 2 |
| 41 | 11,033 | 1 |
| 42 | 11,943 | 1 |
| 43 | 3763 | 3 |
| 44 | 8.483 | 1 |
| 45 | 71,683 | 1 |
| 46 | 15,193 | 1 |
| 47 | 40,693 | 1 |
| 48 | 5,993 | 1 |
| 49 | pounds/63.4 | 1 |
| 50 | 8,904 | 1 |
| 51 | deep/2454 | 1 |
| 52 | 639,064 | 1 |
| 53 | 152,564 | 1 |
| 54 | 3764 | 5 |
| 55 | 4074 | 5 |
| 56 | 2,384 | 2 |
| 57 | low-vsa/cd105 | 1 |
| 58 | 6405 | 1 |
| 59 | 5225 | 3 |
| 60 | 7745 | 2 |
| 61 | 16,555 | 1 |
| 62 | deep/1365 | 1 |
| 63 | 62,565 | 1 |
| 64 | 11,375 | 1 |
| 65 | 115,775 | 1 |
| 66 | pounds/61.6 | 1 |
| 67 | β,16 | 1 |
| 68 | £36.16 | 1 |
| 69 | 4126 | 2 |
| 70 | 4346 | 1 |
| 71 | 8456 | 1 |
| 72 | 0.843-0.970/0.846-0.956 | 1 |
| 73 | 6766 | 2 |
| 74 | 33,776 | 1 |
| 75 | 2,386 | 1 |
| 76 | 37,386 | 1 |
| 77 | 44/107 | 1 |
| 78 | 13,507 | 1 |
| 79 | 10,837 | 1 |
| 80 | 22,947 | 1 |
| 81 | deep/1257 | 1 |
| 82 | 5497 | 2 |
| 83 | 4308 | 3 |
| 84 | 14,608 | 1 |
| 85 | 38,818 | 1 |
| 86 | 5,238 | 3 |
| 87 | 10,948 | 3 |
| 88 | 2,119 | 4 |
| 89 | 22/49 | 1 |
| 90 | 20,059 | 1 |
| 91 | complete.159 | 1 |
| 92 | 9,169 | 1 |
| 93 | 4689 | 3 |
| 94 | 27.1±8.9mpa | 1 |
| 95 | days.data | 1 |
| 96 | patient-fc | 1 |
| 97 | spider-phobic | 4 |
| 98 | mpa/53°c | 1 |
| 99 | sexually-experienced | 1 |
| 100 | «well-grounded | 1 |
| 101 | reported.placebo-controlled | 1 |
| 102 | flavivirus-unprimed | 1 |
| 103 | telephone-screened | 4 |
| 104 | behaviorally-defined | 2 |
| 105 | antipsychotic-stabilised | 1 |
| 106 | tonsillectomised | 2 |
| 107 | hypertensed | 1 |
| 108 | pretransfused | 5 |
| 109 | vedolizumab-treated | 4 |
| 110 | dinoprostone-treated | 1 |
| 111 | icatibant-treated | 3 |
| 112 | immunotreated | 2 |
| 113 | mirna-related | 1 |
| 114 | undistracted | 3 |
| 115 | purposively-selected | 1 |
| 116 | late-detected | 2 |
| 117 | opioid-addicted | 3 |
| 118 | unbelted | 4 |
| 119 | pubmed-indexed | 1 |
| 120 | cholecystectomized | 6 |
| 121 | track-hd | 1 |
| 122 | caregiver/child | 1 |
| 123 | 15-18-year-old | 1 |
| 124 | leptin-resistance | 2 |
| 125 | biased.three | 2 |
| 126 | participants.three | 1 |
| 127 | employed.the | 1 |
| 128 | contactable | 14 |
| 129 | citable | 2 |
| 130 | eligible | 11,656 |
| 131 | study-eligible | 10 |
| 132 | ineligible | 420 |
| 133 | suggestible | 4 |
| 134 | dietary-lifestyle | 1 |
| 135 | prt+tme | 2 |
| 136 | pre-guideline | 3 |
| 137 | performed.nine | 1 |
| 138 | cells/litre | 3 |
| 139 | noncase | 3 |
| 140 | noncomatose | 3 |
| 141 | supervisor-subordinate | 1 |
| 142 | chikv+ve | 2 |
| 143 | biologic-naive | 6 |
| 144 | used.five | 1 |
| 145 | patients.five | 1 |
| 146 | hcv-rna-negative | 2 |
| 147 | elisa-negative | 1 |
| 148 | lge-negative | 2 |
| 149 | sn-negative | 1 |
| 150 | descriptive/qualitative | 1 |
| 151 | fob-positive | 1 |
| 152 | tv-positive | 4 |
| 153 | cytomegalovirus-seropositive | 2 |
| 154 | 'observational/descriptive | 1 |
| 155 | anti-tnf-naïve | 6 |
| 156 | low-ef | 3 |
| 157 | 0.1ng/g | 1 |
| 158 | tru/mg | 1 |
| 159 | commitment-enhancing | 3 |
| 160 | practise-changing | 1 |
| 161 | clerking | 2 |
| 162 | 'preparing | 3 |
| 163 | consenting | 543 |
| 164 | self-paying | 4 |
| 165 | ng/dl.h | 2 |
| 166 | 0.8-3.1h | 1 |
| 167 | adolescent-mlh | 2 |
| 168 | level-iii | 2 |
| 169 | education/work | 1 |
| 170 | 1752±99kcal | 1 |
| 171 | retrospective/observational | 1 |
| 172 | ±93pg/ml | 1 |
| 173 | parent/girl | 1 |
| 174 | pethema/gem | 1 |
| 175 | screening-arm | 3 |
| 176 | postpterygium | 1 |
| 177 | inconsistent.fourteen | 1 |
| 178 | included.eleven | 1 |
| 179 | au*min | 1 |
| 180 | 2-season | 1 |
| 181 | acceptable.placebo | 1 |
| 182 | reviparin/placebo | 1 |
| 183 | g/mo | 3 |
| 184 | 259euro | 1 |
| 185 | identified.two | 1 |
| 186 | tested.two | 1 |
| 187 | observed.two | 1 |
| 188 | infants.two | 1 |
| 189 | training-group | 2 |
| 190 | cont-group | 2 |
| 191 | dalys/year | 4 |
| 192 | smaller/shorter | 1 |
| 193 | youth-caregiver | 1 |
| 194 | patients-four | 1 |
| 195 | performed.four | 1 |
| 196 | pre-tavr | 2 |
| 197 | use-records | 1 |
| 198 | picoamperes | 1 |
| 199 | tumor-associated-antigens | 1 |
| 200 | participating.explanations | 1 |
| 201 | infant/mothers | 1 |
| 202 | noninhibitors | 1 |
| 203 | high-readiness | 2 |
| 204 | race-conscious | 3 |
| 205 | unfit | 154 |
| 206 | protocol-compliant | 2 |
| 207 | seasonal-dependent | 3 |
| 208 | carer/patient | 1 |
| 209 | preadolescent-parent | 1 |
| 210 | patient-parent | 1 |
| 211 | smaller/short | 1 |
| 212 | small.most | 1 |
| 213 | separately.most | 1 |
| 214 | ras-wt | 4 |
| 215 | pn2/3.six | 1 |
| 216 | g/animal/day | 1 |
| 217 | 399.11/qaly | 1 |
| 218 | probably/possibly | 1 |
| 219 | cgycm² | 2 |
| 220 | ng/m³ | 4 |
| 221 | pg/m³ | 1 |
| 222 | µg/g¹ | 1 |